Melphalan, BCNU, vitamin B12, and ascorbic acid plus ASCT show promise for patients with metastatic PDAC, according to results from the SHARON trial.
Kenneth H. Yu, MD
Advertisement
Articles by Kenneth H. Yu, MD
COUNTERPOINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer
Neoadjuvant therapy is an attractive approach with the promise of clinical benefit for patients with surgically resectable pancreatic cancer. However, clinical trial results in support of this approach remain unconvincing.
Advertisement
Latest Updated Articles
Response Rates Show Promise in Phase 1 Trial Involving ASCT in Metastatic PDACPublished: October 28th 2025 | Updated:
COUNTERPOINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic CancerPublished: January 15th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Regular Approval to Rucaparib in Metastatic CRPC
2
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
3
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
4
All-Oral Elacestrant Combos Offer “Tremendous” Benefits in Breast Cancer
5